Hostname: page-component-7b7567c8c-8rbv8 Total loading time: 0 Render date: 2026-11-18T10:39:38.165Z Has data issue: false hasContentIssue false

How do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies

Published online by Cambridge University Press:  09 December 2024

Rémy Dumont
Affiliation:
Assessment and Access to Innovation Direction, Haute Autorité de Santé, Saint-Denis, France
Etienne Lengliné*
Affiliation:
Haematology Department, AP-HP Saint Louis Hospital, Paris, France
Clara Delorme
Affiliation:
Assessment and Access to Innovation Direction, Haute Autorité de Santé, Saint-Denis, France
Jean-Pierre Bru
Affiliation:
Infectious Diseases, Annecy Genevois Hospital, CHANGE, Annecy, France
Sévérine Ansart
Affiliation:
Department of Infectious Diseases, University Hospital of Brest, Brest, France
Elisabeth Aslangul
Affiliation:
Service de Médecine Interne, Hôpital Louis-Mourier, Assistance Publique-Hôpitaux de Paris, Colombes, FranceUPD5, Université Paris-Descartes, Paris, France
Sophie Kelley
Affiliation:
Assessment and Access to Innovation Direction, Haute Autorité de Santé, Saint-Denis, France
Pierre Cochat
Affiliation:
Scientific Board, Haute Autorité de Santé, Saint-Denis, France
Sylvie Chevret
Affiliation:
ECSTRRA Team, Université Paris Cité, Paris, France
Thierno Diatta
Affiliation:
Assessment and Access to Innovation Direction, Haute Autorité de Santé, Saint-Denis, France
*
Corresponding author: Etienne Lengliné; Email: etienne.lengline@aphp.fr
Rights & Permissions [Opens in a new window]

Abstract

Antimicrobial resistance (AMR) has become a worldwide growing concern over the past decades. Thus, encouraging manufacturers to develop new antibiotics is needed. We hypothesised that transparency on the regulatory appraisals of antibiotics would provide an incentive to pharmaceutical development. We thus aimed at reporting the French health technology assessment (HTA) opinions and reimbursement decision on antibiotics to those German (G-BA) and English (NICE) HTA bodies.

A qualitative analysis of the Transparency Committee of the French National Authority for Health (TC-HAS) opinions regarding antibiotics assessment between 2016 and 2020 was performed. Decisions of reimbursement by TC-HAS were compared to those from G-BA and NICE when available. TC-HAS recognized a clinical benefit (CB) for 15/15 evaluated indications, a clinical added value for 9/15, and a public health interest for 8/15. Among the valued antibiotics by HAS, 5 were recommended for restricted use as a “reserve” to protect against the risk of resistance emergence. A comparison of HTA opinions was possible across HTA for only 8 antibiotics. The G-BA granted a reserve status for 4 drugs and NICE a reserve with restricted use for 5 antibiotics. Three of these antibiotics were positioned similarly by the English, German, and French HTA bodies. This qualitative analysis of HTA opinions between different European HTA bodies shows a consistent reimbursement decision of antibiotics against MDR bacteria and tuberculosis besides the differences in the applied assessment methods. This work also shows how HTA bodies could recognize a clinical added value in a context of the emergence of antibiotic resistance.

Information

Type
Commentary
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press
Figure 0

Table 1.German Robert Koch Institute (RKI) indicator list for classifying a new antibiotic as a reserve antibiotic

Figure 1

Table 2.UK criteria for appraisal of new antibiotics proposed by the Office of Health Economics and the Academy of Infection Management

Figure 2

Table 3.Appraisal of 12 antibiotics assessed between 2016 and 2020 by French (HAS), English (NICE), and German (G-BA) HTA bodies

Figure 3

Figure 1.Appraisal by TC-HAS in terms of clinical added benefit of the antibiotic assessed according to date (A) or study design (B). Part A of Figure 1 shows that in 2020, there was more antibiotic with significative clinical added value (CAV III or IV) than in previous years. Part B of Figure 1 shows that the recognition of innovation, resulting in a significative CAV, was supported by more advanced clinical developments, in particular with the completion of phase III clinical trials. The clinical added value (CAV) is an assessment of the therapeutic (or diagnostic) progress provided by a medicinal product – notably in terms of efficacy or safety – compared with existing alternatives. It measures the medical added value of the medicine compared with existing therapies: this assessment is a snapshot at a given point in time within an environment that may evolve. It may be rated major (CAV level I), substantial (CAV level II), moderate (CAV level III), minor (CAV level IV), or no improvement (CAV level V), with the latter level corresponding to no therapeutic progress. The clinical benefit (CB) of a medicinal product in a given indication is assessed on the basis five factors: the efficacy and adverse effects of the medicinal product; its place in the therapeutic strategy, particularly with respect to the other therapies available; the seriousness of the disease targeted by the medicinal product; the preventive, curative or symptomatic nature of the medicinal product; the public health benefit of the medicinal product.

Supplementary material: File

Dumont et al. supplementary material

Dumont et al. supplementary material
Download Dumont et al. supplementary material(File)
File 24.6 KB